СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lira Roseane Lustosa de Santana, Nogueira Flávio Augusto Barros, Campos Rosália de Fátima Penna de Carvalho, Ferreira Dayenne Regina Mota, Roxo Pedro Lucas Brito Tromps, de Azevedo Caio César Santana, Gimenes Eleonôra Costa Monteiro, Bastos Ruan Lucas Costa, Nascimento Camila Evangelista Carnib, Nunes Flávia Danyelle Oliveira, Marques Mayane Cristina Pereira, Campos Carmem Duarte Lima, Martinez Camila Guerra, Zagmignan Adrielle, Silva Luís Cláudio Nascimento, Ribeiro Rachel Melo, de Azevedo Dos Santos Ana Paula Silva, Carvalho Rafael Cardoso, de Sousa Eduardo Martins
Аннотация
Infection by Mycobacterium abscessus subsp. massiliense poses a growing public health threat, especially to immunocompromised individuals. The pathogenicity of this mycobacterium is directly linked to its ability to form biofilms, complex structures that confer resistance to antibiotics and the host immune response. The extracellular matrix of the biofilm acts as a physical barrier, hindering the penetration of drugs and the action of the immune system, while also inducing a slow-growth state that reduces susceptibility to antibiotics. Current therapies, which involve prolonged use of multiple antibiotics, are often ineffective and cause significant side effects. Therefore, it is essential to explore new strategies targeting bacterial resistance and biofilm destruction. This narrative review explores the biofilm-forming capacity of Mycobacterium abscessus subsp. massiliense and the potential of novel therapeutic strategies. Promising approaches include inhibiting biofilm formation, developing drugs with improved penetration of the extracellular matrix, combination therapies with agents that destabilize the biofilm structure, and modulating the host immune response. Investing in research and development of new therapeutic strategies is essential to combat this resistant bacterium and improve patient outcomes.